Open AccessTreatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer
Author(s) -
Mari Tone,
Takehiro Izumo,
Nobuyasu Awano,
Naoyuki Kuse,
Minoru Inomata,
Takeo Jo,
Hirofumi Yoshimura,
Shingo Miyamoto,
Hideo Kunitoh
Publication year - 2019
Publication title -
lung cancer management
Language(s) - English
Resource type - Journals
eISSN - 1758-1974
pISSN - 1758-1966
DOI - 10.2217/lmt-2019-0001
Subject(s) - chemotherapy , salvage therapy , medicine , adverse effect , lung cancer , oncology
Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.